TD Cowen analyst Boris Peaker upgraded Nektar to Outperform from Market Perform. Rezpeg presents a unique mechanism of action and differentiated efficacy in AD and potentially in other autoimmune indications, says the analyst, who sees a favorable risk/reward ahead of Nektar reporting both Phase 2b studies of Rezpeg in AD and alopecia in the first half of 2025. In addition, Nektar has “a strong financial position,” with cash runway into mid-2026, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKTR:
